The age–male–albumin–bilirubin–platelets (aMAP) risk scoring system was recently created to assess HCC risk in chronic hepatitis patients, including HCV carriers with SVR, again both in the presence or absence of cirrhosis. This evidence concerns the gene ALB and hepatocellular carcinoma.